Portland, OR -- (SBWIRE) -- 09/19/2017 -- The thyroid disease occurs mainly due to a deficiency of iodine in the body. It has been observed that over 2 billion individuals have insufficient iodine intake, among which sub-Saharan Africa and South Asia are majorly affected. The introduction of various remedies to treat this deficiency is anticipated to boost the market growth in future.

Access full summary at: https://www.alliedmarketresearch.com/request-toc-and-sample/3762

The factors that drive the growth of the global thyroid gland disorder treatment market are growing patient population with iodine deficiency. In addition, owing to new drug-delivery technologies, companies are increasing their focus on innovative and improved drug formulations that further fuel the market growth. However, the availability of alternative treatment methods such as thyroid surgery and stringent government regulations hamper the market growth. In addition, increasing governmental awareness programs regarding the disease and its treatment is expected to provide lucrative growth opportunities to the market.

The report segments the global thyroid gland disorder treatment market based on disease type and drug type. Based on disease type, the market is divided into hyperthyroidism and hypothyroidism. In terms of drug type, the market is categorized into levothyroxine, liothyronine, propacil, imidazole, and others. Regionally, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players of the global thyroid gland disorder treatment market include AbbVie, Pfizer Inc., Merck & Co., Inc., Allergan plc, Mylan N.V., GlaxoSmithKline plc, Novartis AG, RLC LABS, Inc., Sanofi S.A., and Abbott Laboratories.

Thyroid Gland Disorder Treatment Market Key Segments:

By Disease Type

- Hyperthyroidism
- Hypothyroidism

By Drug Type

- Levothyroxine
- Liothyronine
- Propacil
- Imidazole
- Others

Early buyers will receive 20% customization on this report